ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Make Asthma and Allergy Treatments Accessible for All

Washington, DC, April 30, 2025 (GLOBE NEWSWIRE) -- This year, the Asthma and Allergy Foundation of America (AAFA) continues a tradition started in 1984 - designating May as National Asthma and Allergy Awareness Month. Our focus for 2025: Make asthma and allergy treatments accessible for all.

“Access to essential medicines for asthma and allergies saves lives,” said Kenneth Mendez, president and CEO of AAFA. “This month, we plan to focus attention on policies and programs that improve health outcomes for the more than 100 million people in the United States with asthma and/or allergies. Maintaining and expanding access to health care and medicine will save lives, improve health, and reduce the economic burden of asthma and allergies.”

During the month of May, AAFA will highlight policy changes needed to make healthy living more affordable and accessible. We encourage individuals to reach out to state and national policymakers to urge them to back solutions that protect the health of our community. AAFA emphasizes it is critical to ensure people with asthma and allergic conditions can access essential life-saving medicines that (1) treat the underlying disease and (2) stop symptoms.

AAFA will host a press briefing at the U.S. Capitol and visit congressional offices on World Asthma Day – May 6th – to call attention to challenges faced by people with asthma and allergies and ask Congress to take action.

Specifically, we are calling for: 

  • More affordable asthma and allergy treatments
  • Better health care coverage
  • Reduced barriers to health care
  • Guidelines, regulations, and oversight to support healthy spaces
  • Federal investment in asthma and allergy programs and research

For more information, including a full calendar of events, fact sheets, infographics, and more, visit: aafa.org/awareness.

“Focused, consistent advocacy is essential to improve access to asthma and allergy care and treatments,” said Melanie Carver, chief mission officer at AAFA. “The asthma and allergy community reflects a large portion of the U.S. population. Our community has a very powerful voice to encourage policymakers to bring about needed change.”

AAFA provides advocacy toolkits on topics such as epinephrine stocking, child care policies for food allergy, asthma and allergy school policies, healthy homes and schools, and asthma awareness. Additionally, advocates can take action on current bills and regulations that affect the allergy and asthma community by visiting AAFA’s Advocacy Action Center.  

About AAFA  
Founded in 1953, AAFA is the oldest and largest non-profit patient organization dedicated to saving lives and reducing the burden of disease for people with asthma, allergies, and related conditions through research, education, advocacy, and support. AAFA offers extensive support for individuals and families affected by asthma and allergic diseases, such as food allergies and atopic dermatitis (eczema). Through its online patient support communities, network of regional chapters, and collaborations with community-based groups, AAFA empowers patients and their families by providing practical, evidence-based information and community programs and services. AAFA is the only asthma and allergy patient advocacy group that is certified to meet the standards of excellence set by the National Health Council. For more information, visit: aafa.org and kidswithfoodallergies.org.

Attachment


Andy Spears
Asthma and Allergy Foundation of America
2029741223
media@aafa.org
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.